Table 5.
Incremental Value of GlycA beyond traditional cardiovascular risk factors and Hs-CRP in assessing both Vascular Inflammation and Coronary Artery Disease
| A: Incremental value provided by GlycA in assessing aortic vascular inflammation by 18-FDG PET/CT. | |||
|---|---|---|---|
| Model | Total Cohort | Psoriasis | Control |
| Chi-square (p value) |
Chi-square (p value) |
Chi-square (p value) |
|
| GlycA added to Model 1 | 23.47 (0.0007) | 24.83 (<0.0001) | 5.8 (0.02) |
| Hs-CRP added to Model 1 | 0.96 (0.33) | 0.1 (0.8) | 1.01 (0.32) |
| GlycA added to Hs-CRP in Model 1 | 20.06 (<0.0001) | 19.59 (<0.0001) | 8.95 (0.003) |
| Hs-CRP added to GlycA in Model 1 | 2.54 (0.11) | 0.7 (0.4) | 0.22 (0.64) |
| B: Incremental value provided by GlycA in assessing total burden of coronary artery disease by CCTA. | |||
|---|---|---|---|
| Model | Total Cohort | Psoriasis | Control |
| Chi-square (p value) |
Chi-square (p value) |
Chi-square (p value) |
|
| GlycA added to Model 1 | 15.80 (0.0003) | 8.8 (0.003) | 7.78 (0.003) |
| Hs-CRP added to Model 1 | 1.09 (0.3) | 0.64 (0.42) | 8.12 (0.04) |
| GlycA added to Hs-CRP in Model 1 | 14.34 (0.0003) | 7.88 (0.008) | 6.49 (0.01) |
| Hs-CRP added to GlycA in Model 1 | 0.63 (0.43) | 0.4 (0.55) | 7.22 (0.02) |
Model 1 is adjusted for age, gender, FRS, BMI, HOMA-IR, SBP, LDL-C, HDL-C, smoking and Statin use.
Hs-CRP: High-sensitivity C-reactive protein, FRS: Framingham Risk Score, BMI: Body Mass Index, SBP: Systolic Blood Pressure, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance.